Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2024 08:10 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement
November 18, 2024 08:10 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 06, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
September 17, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
September 10, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
August 07, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
July 16, 2024 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
June 06, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 07, 2024 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
April 30, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...